瑞马唑仑与丙泊酚用于泌尿外科手术全静脉麻醉的疗效:一项随机临床试验
该单中心、前瞻性、单盲、随机、非劣效性试验纳入146例择期泌尿外科手术成人患者,比较瑞马唑仑与丙泊酚复合瑞芬太尼和顺阿曲库铵的全静脉麻醉效果。瑞马唑仑组与丙泊酚组的TIVA成功率分别为100%和98.6%,瑞马唑仑组低血压发生率和麻黄碱用量更低,注射痛更少。
要点
- 瑞马唑仑用于泌尿外科手术TIVA的成功率不劣于丙泊酚。
- 瑞马唑仑组低血压发生率26%,低于丙泊酚组的46.6%。
- 瑞马唑仑组注射痛发生率为0,显著低于丙泊酚组的76.7%。
核心结论
- 瑞马唑仑复合瑞芬太尼和顺阿曲库铵用于泌尿外科手术TIVA的疗效不劣于丙泊酚。
研究设计与样本
- 研究为前瞻性、单盲、随机、非劣效性临床试验,单中心,纳入146例择期泌尿外科手术成人患者,按1:1随机分配至丙泊酚组或瑞马唑仑组。
主要发现
- 瑞马唑仑组和丙泊酚组的TIVA成功率分别为100%和98.6%。
- 瑞马唑仑组麻醉期间低血压发生率为26%,低于丙泊酚组的46.6%(P=0.016)。
- 丙泊酚组麻醉期间麻黄碱总用量中位数[IQR]为10[0至12.5]mg,高于瑞马唑仑组的0[0至10]mg(P=0.0002)。
- 丙泊酚组注射痛发生率为76.7%,显著高于瑞马唑仑组的0(P<0.001)。
- 两组在麻醉深度可控性、麻醉与手术特征及生命体征方面无显著差异。
关键数值与推荐
- 主要结局TIVA成功率的预设非劣效界值为组间绝对差异6%。
- 丙泊酚组诱导时丙泊酚剂量为100 mg min-1以达到BIS 40至60,维持血浆浓度2.5至4 μg ml-1。
- 瑞马唑仑组诱导起始剂量为10 mg kg-1 h-1以达到BIS 40至60,维持剂量0.2至2 mg kg-1 h-1。
临床怎么用
- 对于泌尿外科手术TIVA,瑞马唑仑可作为丙泊酚的替代选择,且低血压和注射痛风险更低。
局限性
- 研究为单中心、单盲设计,样本量有限,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Remimazolam is a novel ultra-short-acting benzodiazepine sedative that acts on the gamma-aminobutyric acid type A receptor (GABAAR). OBJECTIVE: To compare the efficacies of remimazolam (RMZ), and propofol (PROP) combined with remifentanil and cisatracurium for total intravenous anaesthesia (TIVA) in patients undergoing urological surgery. DESIGN: A prospective, single-blind, randomised, noninferiority clinical trial. SETTING: Single centre from 1 January 2022 to 30 March 2022. PATIENTS: A total of 146 adult patients undergoing elective urological surgery. INTERVENTION: Patients were randomly allocated in a 1 : 1 ratio to the PROP or RMZ groups. In the PROP group, anaesthesia was induced with propofol at 100 mg min -1 to reach a bispectral index score (BIS) of 40 to 60. After loss of consciousness (LOC), intravenous fentanyl 3 μg kg -1 was administered, followed by cisatracurium 0.3 mg kg -1 . Patients were intubated 3 min after cisatracurium administration. Anaesthesia was maintained with the combination of propofol (plasma concentration: 2.5 to 4 μg ml -1 ) and remifentanil (plasma concentration: 2.5 to 4 ng ml -1 ). In the RMZ group, anaesthesia was induced with remimazolam tosilate starting at 10 mg kg -1 h -1 to reach a BIS of 40 to 60 and maintained between 0.2 and 2 mg kg -1 h -1 . After LOC, fentanyl and cisatracurium were administered and intubation was performed as in the PROP group. Anaesthesia was maintained with a combination of remimazolam (0.2 to 2 mg kg -1 h -1 ) and remifentanil (plasma concentration: 2.5 to 4 ng ml -1 ). MAIN OUTCOME MEASURES: The primary outcome was the TIVA success rate. The predefined noninferiority margin considered an absolute difference of 6% in the primary outcome between the groups. The secondary outcomes were vital signs, anaesthesia and surgery characteristics, and adverse events. RESULTS: All patients completed the trial. The success rates of TIVA with remimazolam and propofol were 100 and 98.6%, respectively. The incidence of hypotension during anaesthesia was lower in the RMZ group (26%) than in the PROP group (46.6%) ( P = 0.016). The median [IQR] total consumption of ephedrine during anaesthesia was higher in the PROP group 10 [0 to 12.5] mg than in the RMZ group 0 [0 to 10] mg ( P = 0.0002). The incidence of injection pain was significantly higher in the PROP group (76.7%) than in the RMZ group (0; P < 0.001). No significant differences in the controllability of the anaesthesia depth, anaesthesia and surgery characteristics, or vital signs were observed between the groups. CONCLUSION: Remimazolam demonstrated noninferior efficacy to propofol combined with remifentanil and cisatracurium for TIVA in patients undergoing urological surgery. TRIAL REGISTRATION: Chictr.org.cn, identifier: ChiCTR2100050923. CLINICAL REGISTRATION: The study was registered in the Chinese Clinical Trial Registry (ChiCTR2100050923, Principal investigator: Xuehai Guan, Date of registration: 8 November 2021, https://www.chictr.org.cn/showproj.html?proj=133466 ).
引用
- Lan H, Cao H, Liu S, et al. Efficacy of remimazolam tosilate versus propofol for total intravenous anaesthesia in urological surgery: A randomised clinical trial. Eur J Anaesthesiol. 2024. PMID: 38165145. doi:10.1097/EJA.0000000000001938
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。